An Additional Mechanism of Action of Abciximab: Dispersal of Newly Formed Platelet Aggregates
Stanley J. Marciniak, Mary Ann Mascelli(Unknown), Alan D. Michelson(Harvard University), Andrew L. Frelinger(University of Nottingham), Peter Marchese(University of Massachusetts Chan Medical School), Robert E. Jordan(Baylor College of Medicine), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Mark Furman(Royal Free London NHS Foundation Trust)
Cited by 89
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
|The Lancet|2009|723
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617